KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Current Deferred Revenue (2016 - 2022)

Inovio Pharmaceuticals (INO) has disclosed Current Deferred Revenue for 13 consecutive years, with $9.0 million as the latest value for Q2 2022.

  • Quarterly Current Deferred Revenue rose 8131.27% to $9.0 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Jun 2022, up 8131.27% year-over-year, with the annual reading at $21628.0 for FY2021, 53.62% down from the prior year.
  • Current Deferred Revenue hit $9.0 million in Q2 2022 for Inovio Pharmaceuticals, up from $15378.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $9.0 million in Q2 2022 to a low of $14853.0 in Q2 2020.
  • Historically, Current Deferred Revenue has averaged $746658.9 across 5 years, with a median of $92353.0 in 2019.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 94.56% in 2018 and later surged 8131.27% in 2022.
  • Year by year, Current Deferred Revenue stood at $223577.0 in 2018, then plummeted by 58.69% to $92353.0 in 2019, then plummeted by 49.51% to $46628.0 in 2020, then crashed by 53.62% to $21628.0 in 2021, then skyrocketed by 41432.36% to $9.0 million in 2022.
  • Business Quant data shows Current Deferred Revenue for INO at $9.0 million in Q2 2022, $15378.0 in Q1 2022, and $21628.0 in Q4 2021.